|
Just Four Years Ago, a Pharmaceutical company that Goes By The Name of Vermillion, Inc. (VRML) Rocketed from 5-Cents to More Than 30-Dollars per Share for an Astounding +60,000% Gain!
Every Single Year there are a Few Pharmaceutical Penny Stocks that make Similar Moves...
We Suspect that AXXE (Axxess Pharma Inc.) could be that Next HUGE Pharmaceutical Winner!
 Axxess Pharma Inc. (AXXE) is a Nevada Corporation operating through its wholly-owned Canadian Subsidiary, Axxess Pharma Canada Inc., headquartered in Toronto that is dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas.
Specializing in the marketing and distribution of both prescription and non-prescription medical products in niche markets, AXXE’s 23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, high cholesterol, blood pressure, acute pain, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more.
The company has recently Entered into a Memorandum of Understanding with TapouT, a well-known Mixed Martial Arts Brand, in which AXXE will receive worldwide exclusive rights to market and sell a full line of pain relief and muscle recovery products, as well as develop and market a vitamin line under the TapouT brand. This will provide AXXE with an additional six products that are ready to launch and, when the deal is finalized, will launch globally as the TapouT brand gains footholds in other major countries such as Brazil, India and China. Additionally, the company anticipates launching a second wave of TapouT branded products in 2014 that will consist of a premium vitamin line.
Further expansion includes AXXE’s Recent Licensing Agreement with a Canadian manufacturer of cancer drugs, Biolyse Pharma Corporation, in which the company now has full rights to a suite of cancer drugs for the Mexican market. The first drug will be paclitaxel, a cancer drug used as first-line therapy in a number of cancers such as breast, ovarian, lung, head and neck.
Website: www.AXXEsspharmainc.com
 On Monday Night AXXE released Breaking News!
The company just announced that it has Signed an Agreement with a Leading Mexican Pharmaceutical company, Industria Farmaceutica Andromaco, S.A. de C.V., to market it's New Product, Soropon, in Mexico...
AXXE's Soropon is a medicated shampoo for the treatment of cradle cap in infants and a severe form of dandruff in seniors (Seborrheic dermatitis).
Dr. Daniel Bagi, President of Axxess Pharma, stated: "With a population three times that of Canada's and a higher birth rate than Canada's, Axxess is extremely pleased with the market possibilities in Mexico for Soropon and we anticipate robust sales for Soropon in Mexico, starting in 2014."
Just Last Week, AXXE announced that it is in the process to Acquire a Leading Canadian OTC Healthcare Company.
The Canadian Corporation, based in Toronto, has an attractive IP portfolio including a best-selling, patented, OTC pain relief formula. The company also has a number of unique formulas and world class brand products that Axxess Pharma will be able to immediately leverage, with existing distribution.
Dr. Bagi, President of Axxess Pharma Inc. stated, "We anticipate completing the final agreement within 30 days. This acquisition will facilitate access to capital and generate a rapid ramp-up of sales. We anticipate major revenue growth in the near term with this acquisition."
You read that correct... AXXE's CEO 'anticipates MAJOR Revenue Growth in the Near-Term'!
About One Month Ago, Two-Time Canadian Heavyweight Boxing Champion, Ray Olubowale, was made Spokesperson and Corporate Ambassador of AXXE...
Celebrity Endorsements tend to be Very Positive in Regards to Increasing Product Sales!
As we already mentioned above, AXXE has also Entered into a Memorandum of Understanding with TapouT, a well-known Mixed Martial Arts Brand, in which AXXE will receive worldwide exclusive rights to market and sell a full line of pain relief and muscle recovery products, as well as develop and market a vitamin line under the TapouT brand.
In 2009, TapouT generated $200 million in revenues, more than 16 times its $12 million revenue in 2006...
This NEW Relationship with TapouT could drive in Substantial Revenue for AXXE!
AXXE also recently announced that Neil Mellow was Appointed of Senior VP of Sales and Marketing
Mr. Neil Mellor’s previous experience includes managing a pharmaceutical product grow to over $200 million and eventually becoming Canada’s 2nd largest prescription drug.
 With All this Great News from AXXE, it is No Wonder that Trading Volume has been so Significant as of Late!
Did we Mention that AXXE is currently priced at just 50-Cents per Share?
AXXE is Extremely Volitale in a Positive Way; it literally hit both the 52-Week High ($1.04) and 52-Week Low ($0.45) Last Week!
Fortunately for us, AXXE closed Yesterday's Session on the Low End of the Spectrum; just 9.84% Above it's 52-Week Low...
At the Current Price-Level, AXXE's Upside Potential appears to heavily outweigh Downside Risk!
Review AXXE's 6-Month Chart (Below) and you'll likely Understand Exactly what we mean...
Those who Secure Shares of AXXE at the Current PPS could see Enormous Profits...
We suspect that this 'Red Hot Pharmaceutical Stock' will surge past the $1 Mark Again in the Near-Term!
Make sure AXXE should be on the Top of your Watchlist Today...
|
Like
